$29.02
-1.99 (-6.42%)
Open$31.11
Previous Close$31.01
Day High$33.04
Day Low$28.84
52W High$45.22
52W Low$20.51
Volume—
Avg Volume266.1K
Market Cap152.58M
P/E Ratio57.62
EPS$0.55
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+15.6% upside
Current
$29.02
$29.02
Target
$33.56
$33.56
$24.17
$33.56 avg
$46.23
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 10.92M | 10.43M | 9.09M |
| Net Income | 2.59M | 2.46M | 2.32M |
| Profit Margin | 23.7% | 23.6% | 25.5% |
| EBITDA | 3.77M | 3.49M | 2.84M |
| Free Cash Flow | 3.86M | 3.25M | 2.35M |
| Rev Growth | +16.5% | +12.7% | +12.2% |
| Debt/Equity | 1.32 | 1.45 | 0.94 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |